文献速递妇科肿瘤

帕博利珠单抗联合仑伐替尼治疗复发性妇科透明细胞癌(LARA):多中心单臂2期试验

Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2026-01-15

LARA研究是一项多中心单臂2期试验,评估帕博利珠单抗联合仑伐替尼在复发性妇科透明细胞癌患者中的初步活性与安全性。27例患者接受治疗,25例纳入主要分析,24周客观缓解率为40%(95%CI 21-61)。3-4级治疗相关不良事件发生率为52%,无治疗相关死亡。

要点

  • 帕博利珠单抗联合仑伐替尼在复发性妇科透明细胞癌中24周客观缓解率达40%。
  • 3-4级治疗相关不良事件发生率为52%,最常见为高血压(22%)。
  • 所有肿瘤均为错配修复 proficient 或微卫星稳定,仍观察到抗肿瘤活性。

核心结论

  • 帕博利珠单抗联合仑伐替尼在复发性妇科透明细胞癌中显示出有前景的抗肿瘤活性和可控的安全性,支持在随机对照试验中进一步评估。

研究设计与样本

  • 多中心、单臂、2期试验(LARA),在新加坡和韩国三家三级医院开展。
  • 纳入成人(≥18岁)组织学确诊的妇科透明细胞癌患者,既往至少一线含铂化疗后进展或复发,ECOG体能状态评分0-1,未接受过免疫检查点抑制剂治疗。
  • 患者接受帕博利珠单抗200 mg静脉注射每3周一次联合仑伐替尼20 mg口服每日一次,直至疾病进展、不可接受毒性或撤回知情同意,最长2年。
  • 主要终点为治疗前24周内研究者根据RECIST版本1.1评估的客观缓解率,采用改良意向性分析。
  • 共评估30例患者,27例(90%)接受至少一剂研究治疗,25例(83%)纳入主要结局分析。

主要发现

  • 25例可评估患者中,10例在24周内确认客观缓解,24周客观缓解率为40%(95%CI 21-61)。
  • 27例患者中,3-4级治疗相关不良事件发生于14例(52%),最常见为高血压6例(22%)、血小板计数降低2例(7%)、天冬氨酸氨基转移酶升高2例(7%)、丙氨酸氨基转移酶升高2例(7%)。
  • 严重不良事件发生于5例(19%),最常见为免疫相关肝炎2例(7%)和血小板计数降低2例(7%)。
  • 未发生治疗相关死亡。

关键数值与推荐

  • 24周客观缓解率:40%(95%CI 21-61),基于25例改良意向性分析人群。
  • 3-4级治疗相关不良事件发生率:52%(14/27)。
  • 常见3-4级治疗相关不良事件:高血压22%(6/27)、血小板计数降低7%(2/27)、AST升高7%(2/27)、ALT升高7%(2/27)。
  • 严重不良事件发生率:19%(5/27)。

临床怎么用

  • 对于既往含铂化疗后进展或复发的妇科透明细胞癌患者,帕博利珠单抗联合仑伐替尼可作为潜在治疗选择,尤其适用于错配修复 proficient 或微卫星稳定肿瘤。
  • 治疗期间需重点监测高血压、血小板减少和肝毒性等3-4级不良事件,及时处理免疫相关不良事件。
  • 该联合方案的活性需在随机对照试验中进一步验证。

局限性

  • 单臂设计,样本量较小(27例接受治疗,25例纳入主要分析),结果需随机对照试验验证。
  • 研究正在进行中,随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combined targeting of angiogenic and immune pathways is an emerging strategy in clear cell carcinomas arising from the gynaecological tract (CCGCs), given the unique molecular and microenvironmental features of this gynaecological cancer. We aimed to evaluate the preliminary activity and safety of pembrolizumab plus lenvatinib in patients with recurrent CCGC. METHODS: We conducted a multicentre, single-arm, phase 2 trial (LARA) across three tertiary hospitals in Singapore and South Korea. Adult patients (aged ≥18 years) with histologically confirmed CCGC, which had progressed or recurred after at least one previous line of platinum-based chemotherapy; an Eastern Cooperative Oncology Group performance status score of 0-1; and no previous exposure to immune checkpoint inhibitor therapy were eligible for inclusion. Patients received 200 mg intravenous pembrolizumab every 3 weeks plus 20 mg oral lenvatinib daily, until disease progression, unacceptable toxicity, or withdrawal of consent, whichever occurred first, for up to 2 years. The primary endpoint was objective response rate in the first 24 weeks of treatment, as per investigator-assessed Response Evaluation Criteria in Solid Tumours (RECIST; version 1.1), analysed by modified intention to treat. This trial is registered with ClinicalTrials.gov (NCT04699071) and is ongoing. FINDINGS: Between March 26, 2021, and Oct 10, 2023, 30 patients were assessed for eligibility, of whom 27 (90%) participants received at least one dose of pembrolizumab plus lenvatinib. 25 (83%) patients were included in the primary outcome analysis. Median participant age was 52 years (IQR 40-66). Among the 27 patients, 12 (44%) were Chinese, 12 (44%) were Korean, two (7%) were Malay, and one (4%) was Filipino. 24 (89%) patients had primary ovarian clear cell carcinoma; three (11%) had primary endometrial cancer. All tumours had proficient mismatch repair or microsatellite stability. At data cutoff on March 19, 2025, median follow-up was 21·0 months (IQR 12·5-25·2). Ten of 25 patients had confirmed objective response within 24 weeks (objective response rate at 24 weeks 40% [95% CI 21-61]). Grade 3-4 treatment-related adverse events occurred in 14 (52%) of 27 patients, the most common of which were hypertension (six [22%] patients), decreased platelet count (two [7%]), elevated aspartate aminotransferase (AST; two [7%]), and elevated alanine aminotransferase (ALT; two [7%]). Serious adverse events occurred in five (19%) patients, the most common of which were immune-related hepatitis in two (7%) patients and decreased platelet count in two (7%) patients. No treatment-related deaths occurred. INTERPRETATION: Pembrolizumab plus lenvatinib showed promising anti-tumour activity and manageable safety in patients with recurrent CCGC, including in patients with disease progression following previous treatment with anti-angiogenic therapy. These findings support further evaluation of this combination in randomised controlled trials. FUNDING: National Medical Research Council (Singapore), Pangestu Family Foundation Gynaecological Cancer Research Fund, and MSD.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Ngoi NYL, Lee JY, Lim D, et al. Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2026. PMID: 41548565. doi:10.1016/S1470-2045(25)00662-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。